Swedish Orphan Biovitrum markets Kineret internationally following a licence agreement with Amgen.
Kineret is an anti–cytokine, injectable, protein drug used together with methotrexate to treat rheumatoid arthritis.
Treatment with with modern biological drugs aims at blocking the negative effect of the inflammatory cytokines in patients with RA. Kineret uniquely acts by blocking Interleukin-1 receptors.